These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36824969)

  • 21. Upregulation of HLA-II related to LAG-3
    Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
    Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma.
    Wouters R; Bevers S; Riva M; De Smet F; Coosemans A
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [
    Nagle VL; Henry KE; Hertz CAJ; Graham MS; Campos C; Parada LF; Pandit-Taskar N; Schietinger A; Mellinghoff IK; Lewis JS
    Clin Cancer Res; 2021 Apr; 27(7):1958-1966. PubMed ID: 33495310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tracking Human Immunodeficiency Virus-1 Infection in the Humanized DRAG Mouse Model.
    Kim J; Peachman KK; Jobe O; Morrison EB; Allam A; Jagodzinski L; Casares SA; Rao M
    Front Immunol; 2017; 8():1405. PubMed ID: 29163484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.
    Yeo AT; Shah R; Aliazis K; Pal R; Xu T; Zhang P; Rawal S; Rose CM; Varn FS; Appleman VA; Yoon J; Varma H; Gygi SP; Verhaak RGW; Boussiotis VA; Charest A
    Cancer Immunol Res; 2023 May; 11(5):629-645. PubMed ID: 36881002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune involvement of the contralateral hemisphere in a glioblastoma mouse model.
    Crommentuijn MHW; Schetters STT; Dusoswa SA; Kruijssen LJW; Garcia-Vallejo JJ; van Kooyk Y
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
    Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
    MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.
    Meraz IM; Majidi M; Meng F; Shao R; Ha MJ; Neri S; Fang B; Lin SH; Tinkey PT; Shpall EJ; Morris J; Roth JA
    Cancer Immunol Res; 2019 Aug; 7(8):1267-1279. PubMed ID: 31186248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
    Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
    FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
    Liu WN; Fong SY; Tan WWS; Tan SY; Liu M; Cheng JY; Lim S; Suteja L; Huang EK; Chan JKY; Iyer NG; Yeong JPS; Lim DW; Chen Q
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
    Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J
    Front Immunol; 2021; 12():607282. PubMed ID: 33854497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
    Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W
    Elife; 2020 Sep; 9():. PubMed ID: 32909947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
    Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
    Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
    J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma.
    Chen L; Zhou C; Chen Q; Shang J; Liu Z; Guo Y; Li C; Wang H; Ye Q; Li X; Zu S; Li F; Xia Q; Zhou T; Li A; Wang C; Chen Y; Wu A; Qin C; Man J
    Mol Ther Oncolytics; 2022 Mar; 24():522-534. PubMed ID: 35229030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma.
    Dees KJ; Koo H; Humphreys JF; Hakim JA; Crossman DK; Crowley MR; Nabors LB; Benveniste EN; Morrow CD; McFarland BC
    Neurooncol Adv; 2021; 3(1):vdab023. PubMed ID: 33758825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas.
    Choi SH; Stuckey DW; Pignatta S; Reinshagen C; Khalsa JK; Roozendaal N; Martinez-Quintanilla J; Tamura K; Keles E; Shah K
    Clin Cancer Res; 2017 Nov; 23(22):7047-7058. PubMed ID: 28912136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.